CAXTON CORP - Q2 2018 holdings

$283 Million is the total value of CAXTON CORP's 25 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 0.0% .

 Value Shares↓ Weighting
BRKB  BERKSHIRE HATHAWAY INC DELcl b new$1,738,000
-6.5%
9,3120.0%0.61%
-69.5%
JBGS  JBG SMITH PPTYS$1,501,000
+8.1%
41,1700.0%0.53%
-64.8%
UHAL  AMERCO$962,000
+3.2%
2,7000.0%0.34%
-66.4%
PCG  PG&E CORP$958,000
-3.0%
22,5000.0%0.34%
-68.4%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2018-08-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
MOLECULAR TEMPLATES INC24Q2 202330.7%
STRONGBRIDGE BIOPHARMA PLC22Q3 202173.1%
GARRISON CAP INC18Q3 20209.9%
BERKSHIRE HATHAWAY INC DEL17Q3 20195.8%
EIGER BIOPHARMACEUTICALS INC17Q3 20221.7%
AGILE THERAPEUTICS INC16Q1 201855.5%
KALA PHARNACEUTICALS INC16Q4 202117.6%
CM FIN INC16Q1 20197.8%
SYNTA PHARMACEUTICALS CORP15Q2 201699.9%
CTI BIOPHARMA CORP14Q4 20218.7%

View CAXTON CORP's complete holdings history.

Latest significant ownerships (13-D/G)
CAXTON CORP Q2 2018 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Addex Therapeutics Ltd.February 14, 2023718,8490.9%
Cardiff Oncology, Inc.February 14, 2023983,6072.2%
Rezolute, Inc.February 14, 20231,860,5185.0%
Xeris Biopharma Holdings, Inc.February 14, 20235,973,3244.4%
CTI BIOPHARMA CORPFebruary 14, 20222,239,3002.3%
Sierra Oncology, Inc.February 14, 20221,119,3227.0%
Strongbridge Biopharma plcSold outJanuary 05, 202200.0%
SUNESIS PHARMACEUTICALS INCSold outFebruary 16, 202100.0%
Alcentra Capital CorpFebruary 14, 20201,005,0007.8%
Garrison Capital Inc.February 14, 20201,223,0967.6%

View CAXTON CORP's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR2024-05-15
13F-HR2024-02-14
SC 13G/A2024-02-13
SC 13G/A2024-02-13
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
SC 13G/A2023-02-14
SC 13G/A2023-02-14
SC 13G/A2023-02-14

View CAXTON CORP's complete filings history.

Compare quarters

Export CAXTON CORP's holdings